Leukemia, Myeloid, Acute
Conditions
Brief summary
This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.
Detailed description
The given pilot clinical trial of a medicinal product for medical use, is held to evaluate preliminary efficacy and safety/tolerability profiles of antroquinonol in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible.
Interventions
DRUGAntroquinonol
Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
Sponsors
Golden Biotechnology Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of relapsed AML after at least 1 chemotherapy regimen or at initial diagnosis when no intensive treatment possible (based on standard criteria). 2. Men and women 18 to 70 years of age. 3. ECOG performance status = 0 or 1. 4. Ability to comply with the study requirements and give written informed consent. 5. Expected survival more than 3 months. 6. Patients with preserved reproductive potential agree to use, with their partner, adequate contraception throughout the study and for 30 days thereafter (contraceptive methods with reliability greater than 90%: cervical caps with spermicide, diaphragms with spermicide, condoms with intravaginal spermicide, non-hormonal intrauterine devices), or true sexual abstinence.
Exclusion criteria
1. Acute promyelocytic leukemia (APL). 2. Hemoglobin ≤ 7g/dL or platelet ≤ 50,000. 3. Abnormal liver and renal function: * Total bilirubin \> 2 mg/dL; * AST and ALT \> 2.5 × ULN; * Creatinine \> 1.5 × ULN, OR creatinine clearance \< 50 mL/min/1.73m2. 4. The subject has not recovered to grade ≤ 1 adverse events due to investigational or chemotherapeutic drugs or stem cell transplantation which were administered \> 4 weeks prior to study enrollment. 5. Patient who has had in the past 3 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ ductal carcinoma of the breast. 6. Subjects with any serious active infection (i.e., requiring an intravenous antibiotic, antifungal, or antiviral agent). 7. Subjects with known human immunodeficiency virus, active hepatitis B or C. 8. Subjects who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise subject safety or interfere with the evaluation of the safety of the study drug. 9. Known or suspected substance abuse or alcohol abuse. 10. Patients with history of seizure disorders or central nervous system leukemia. 11. Patients with uncontrolled, intercurrent illness including, but not limited to, symptomatic neurological illness; active, uncontrolled, systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; significant pulmonary disease or hypoxia; or psychiatric illness/social situations that would limit compliance with study requirements. 12. Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea e.g., Crohn's disease, malabsorption, or CTCAE Grade \> 2 diarrhea of any etiology at baseline. 13. Prior major surgery or trauma within 28 days prior to first dose of study drug. 14. A positive urine pregnancy test (strip) for female patients of childbearing potential.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete blood count measurements according International Working Group (IWG) response criteria | 2 weeks | Evaluation of preliminary efficacy profile of antroquinonol in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants alive at 4weeks | 4 weeks | patients' situation |
| Number of Participants alive at 24 weeks | 24 weeks | patients' situation |
Countries
Russia
Outcome results
None listed